AzTrials
AzTrials

Congenital Heart Disease (CHD)NCT07585175

Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood

An observational study of Congenital Heart Disease (CHD), run by Ottawa Heart Institute Research Corporation at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Adults with congenital heart disease (CHD) are a growing patient population in need of ongoing specialized care. Lapses in appropriate transition and transfer processes from childhood to adulthood in CHD care can lead to loss in follow up, late detection of new or evolving cardiac complications and negative patient… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Congenital Heart Disease (CHD)
What is being tested?
Multi-pronged transfer program
How many people
200 participants
Where
1 siteCanada
Study dates
1 Jun 2024to 31 Dec 2026
How long will I take part?
2 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with congenital heart disease (CHD) referred from the pediatric hospital and the community to the University of Ottawa Heart Institute.

Who may be able to join

  • All new patients with congenital heart disease referred from the pediatric hospital and the community

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Joanne N Joseph, MD contact

613-261-9316

joajoseph@ottawaheart.ca

Canada1 site, 1 recruiting
  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y4W7

    Markus Schwerzmann, MD, 613-696-7209, mschwerzmann@ottawaheart.ca

    Keren Mbondo Kasuku, HBSc, kmbondo@ottawaheart.ca

    Recruiting

Other trials in Canada

About this study

Official title: Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood.

Adults with congenital heart disease (CHD) are a growing patient population in need of ongoing specialized care. Lapses in appropriate transition and transfer processes from childhood to adulthood in CHD care can lead to loss in follow up, late detection of new or evolving cardiac complications and negative patient outcomes. Therefore, it is vital that a robust transition and transfer process is established. Through a retrospective study completed recently at the University of Ottawa Heart Institute (UOHI) we have shown that the average wait time to be assessed by an adult congenital heart disease (ACHD) specialist is about 10 months and within this wait period 1 in 8 ACHD patients have a decline in their health.

The goal of this study is to specifically reduce negative patient outcomes during this wait period. We aim to achieve this by (i) establishing a program to ensure early detection of patients at risk of deterioration and (ii) providing additional support to these patients. The program is designed to have a multipronged approach including tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.

Read more

We plan to improve our transition care by creating a multi-pronged transfer program specifically for patients on the wait list composed of a nurse check in, creation of a diagnosis summary, education day and combined pediatric cardiology/ACHD handover videocall (described below). This program is planned as part of our care pathway and will be offered to all patients on the wait list. We intend to document the efficacy of this transition program to improve transition care by assessing patient reported outcomes and clinical outcomes of the patients who consent to complete additional questionnaires.

The multi-pronged program will include the following:

  1. ACHD nurse check-in (patient check-in via phone call or zoom from the ACHD nurse within 1 month of receiving referral) - allows early establishment of clinical relationship with the patient, screen for risk factors for deterioration and provision of ACHD clinic contact information to enable open line of communication. Patients considered at risk for deterioration on the wait-list based on this check-in conversation will be triaged for a more urgent first consult at the ACHD clinic.
  2. Quick glance diagnosis summary (Electronic on Epic MyChart) - will be created during nurse check in and will be used to disseminate concise patient specific information among health care workers and acts as a reference for the patients.
  3. Organization of an ACHD patient education day (half day hybrid event every 6 months) - allows formal introduction to the ACHD team, provides information session on ACHD care and lowers patients' threshold to inform the ACHD team in case of clinical deterioration.
  4. Combined pediatric cardiology and ACHD handover video call at time of transfer - allows effective and efficient handover of patient care from pediatric to adult care and facilitates the coordination of care during the transfer period.

These four components of the program work together to provide tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.

Read the detailed description

This is a prospective quality improvement study, investigating the effectiveness of a structured multi-pronged transfer program on clinical outcomes and patient-reported outcomes. This program is planned as part of our care pathway and will be offered to all patients on the wait list. Charts of all patients enrolled in this transfer program will be reviewed to assess clinical outcomes. Further voluntary study participation will include an additional survey to assess patient reported outcomes. The patients willing to complete the survey will be consented verbally by the ACHD nurse. The surveys then will be delivered by the nurse using phone or zoom platform to those consenting to participate. Data collection from chart review and surveys will be performed by a research coordinator (KM).

There are 4 components of the transfer program. Groups of patients will be staggered so that the first 50 patients receive 1+2, next 50 patients receive 1+2+3 and the rest of the patients receive 1+2+3+4 as listed below:

  1. ACHD nurse check-in
  2. Quick glance diagnosis summary
  3. ACHD patient education day
  4. Combined pediatric cardiology and ACHD handover video call at time of transfer

Individual component described below:

  1. ACHD nurse check-in via phone or zoom will be completed within 1 month of receiving referral.
  2. Patients referred from CHEO and community will be called by the ACHD nurse within 1 month of receiving the referral as part of the ACHD nurse check-in.
  3. ACHD nurse check-in template will be uploaded to patient chart on Epic. It will include the following (details attached as a separate document):
  4. Access to family physician. ii. Assess patient's knowledge on their cardiac condition. iii. Patient' social circumstance. iv. Patient's dental health. v. Patient's lifestyle habits. vi. Any active cardiac symptoms. vii. Need to expedite ACHD cardiologist appointment. If patient meets any of the following criteria, then patient will be flagged as needing expedited cardiologist appointment:
  5. Worsening arrhythmias (i.e. new or more frequent/intense symptomatic palpitations or new sustained arrythmias) 2. Decreasing exercise intolerance 3. Change in NYHA class 4. Syncope 5. Exercise induced chest pain 6. Peripheral edema or unexplained weight gain viii. Gage interest in patient education day. c. The nurse will also complete the quick glance diagnosis summary for the patient during this check in which is outlined below.
  6. Initial assessment of patient reported outcomes (PROs) will be completed in the form of an additional survey for the patients who consent to participate.
  7. Quick glance diagnosis summary will be completed and provided to the patient.
  • This will be completed by the ACHD nurse at the time of the ACHD nurse check in (within 1 month of receiving the referral).
  • This will be created electronically on the patient's Epic chart under letter/ communications section, which can also be accessed by the patients via their MyChart.
  • The content will be reviewed by ACHD specialist to ensure accuracy.
  • The components of the quick glance diagnosis summary have been reviewed by our patient partner and deemed helpful.
  • The quick glance diagnosis summary will include (details attached as a separate document):
  • Patient name
  • Date of birth
  • Name of ACHD cardiologist
  • Congenital heart disease diagnosis
  • Main surgical/ percutaneous intervention
  • Cardiac device
  • Previous infective endocarditis/ need for endocarditis prophylaxis.
  • Exercise restriction
  • Need for bubble filters on intravenous lines
  • Anti-coagulation
  • Contraception
  • Alarm symptoms to monitor
  • Recommended vaccines
  • Contact information for ACHD clinic
  1. Organization of patient education day for all patients on the waitlist. This is a half day event. Ideally this event will occur every 6 months and would include both patients referred from CHEO as well as the community. Participation will be documented.
  • The education day will include:
  • Formal introduction to ACHD team including nurses and physicians
  • Tour of UOHI facility including clinic/ echo lab
  • Education session emphasizing need for lifelong follow-up, regular exercise, monitoring of alarm symptoms. Session facilitated by dietitian, social worker, psychologist, physiotherapist
  • Networking
  • Option for in-person and virtual component 4) Combined Pediatric cardiology and ACHD handover video calls.
  • Allows effective and efficient handover of patient care from pediatric to adult care team.
  • Will occur after the patient's last pediatric cardiology appointment. This component of the transfer program cannot be offered to patients referred from the community.

Variables to be collected:

Within the first month of being on the ACHD waitlist the following will be completed for all patients (whether or not consenting to participate in the voluntary survey):

  • Electronic Quick glance diagnosis summary created on Epic MyChart (described above)
  • ACHD nurse check via phone and documented on Epic (described above)

During the 1 month ACHD nurse check in, the following information will be collected in the form of a survey (in addition to the standard ACHD nurse check in template) only from those consenting to participate (details attached separately):

  • Age/ date of birth (mm/yyyy)
  • Sex/gender
  • Ethnicity/ race
  • Socioeconomic status (student/ employed/ unemployed)
  • Access to family physician
  • Knowledge assessment related to CHD
  • Initial patient reported outcomes (PROS):
  • Quality-of-life score on linear analog scale9 during the waiting period
  • Patient Health Questionnaire (PHQ9) score10,11 for depression
  • General Anxiety Disorder (GAD-7) score12,13 for anxiety
  • Satisfaction with life survey score14

At time of first ACHD clinic appointment after completing wait list, the following variables will be collected:

  • From chart review (all patients):
  • Duration on wait list
  • Date of first ACHD clinic appointment
  • Number of non-planned ED visits during the wait period
  • Number of unexpected hospital admissions during the wait period
  • Number of family physician visits related to CHD during the wait period
  • Number of urgent interventions planned.
  • From patient survey (in patients consenting to complete the surveys)
  • Assessment of emotional distress related to wait period
  • Knowledge assessment related to CHD
  • Repeat patient reported outcomes (PROS) collected in the form of surveys:
  • Quality-of-life score on linear analog scale9 during the waiting period
  • Patient Health Questionnaire (PHQ9) score10,11 for depression
  • General Anxiety Disorder (GAD-7) score12,13 for anxiety
  • Satisfaction with life survey score14
Being tested
Multi-pronged transfer program
Keywords
Adult Congenital Heart Disease, Transfer of care, Transition of care
Medical subject headings
Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multi-pronged transfer programOther

    There are 4 components of the transfer program. Groups of patients will be staggered so that the first 50 patients receive 1+2, next 50 patients receive 1+2+3 and the rest of the patients receive 1+2+3+4 as listed below:

    1. ACHD nurse check-in
    2. Quick glance diagnosis summary
    3. ACHD patient education day
    4. Combined pediatric cardiology and ACHD handover video call at time of transfer
Study groups in NCT07585175
Study groupRoleWhat they receive
Patients with congenital heart disease referred to the University of Ottawa Heart InstituteWe aim to include all the patients referred to the UOHI ACHD program in our multipronged transfer program. This will include patients from the pediatric hospital (CHEO) and community referrals.
Receives: Other: Multi-pronged transfer program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hospitalizations

    Number of unexpected hospitalizations related to patient's cardiac condition during the wait period.

    Measured: 2 years

  2. Doctor visits related to cardiac conditions

    Number of family physician visits related to patient's cardiac condition during the wait period.

    Measured: 2 years

  3. Unexpected urgent intervention

    Number of urgent intervention related to the cardiac conditions during the wait period.

    Measured: 2 years

  4. Emergency Room Visits

    Number of non-planned emergency department visits related to patient's cardiac condition during the wait period.

    Measured: 2 years

Secondary outcomes (3)
  1. Change in Patient Health Questionnaire (PHQ9) score for depression

    Patient reported outcomes, scored form 0-27, with higher scores indicating greater severity

    Measured: 2 years

  2. Change in General Anxiety Disorder (GAD-7) score for anxiety

    Patient reported outcomes, scored from 0 to 21, with higher scores indicating greater severity.

    Measured: 2 years

  3. Change in Satisfaction With Life Survey (SWLS) score

    Patient reported outcomes, scored from 5 to 25, with higher scores indicating greater life satisfaction.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2026
  2. Study start1 Jun 2024
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07585175
Sponsor's protocol ID
QI - 212
Status last verified
Jun 2026
First submitted
24 Oct 2024
Last updated
2 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Congenital Heart Disease (CHD), run by Ottawa Heart Institute Research Corporation at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joanne N Joseph, MD (613-261-9316, joajoseph@ottawaheart.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hospitalizations (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in